Amgen investor relations material

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. Its products include Aranesp to treat anemia; Neulasta to treat neutropenia; EPOGEN and Procrit to treat anemia; Sensipar/Mimpara to treat secondary hyperparalytic and hypercalcemia; Xgeva for skeletal-related events prevention; Vectibix to treat colorectal cancer; NEUPOGEN to stimulate production of white blood cells in cancer patients undergoing chemotherapy; and ENBREL a tumor necrosis factor blocker to treat rheumatoid arthritis polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis diseases or conditions.